サンプル依頼リスト カート
  • English
  • Korean
表紙：慢性免疫性血小板減少症の世界市場-2023年～2030年
市場調査レポート
商品コード
1372611

慢性免疫性血小板減少症の世界市場-2023年～2030年

Global Chronic Immune Thrombocytopenia Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
慢性免疫性血小板減少症の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

慢性免疫性血小板減少症（ITP）は自己免疫性の出血性疾患であり、血小板分泌の低下により血液凝固が阻害されます。平均的な血小板数は血液1マイクロリットル（μL）あたり約15万～40万です。血小板数が10万/μLより少ない場合は、免疫性血小板減少症に罹患している可能性があります。

Journal of Yeungnam Medical Science, 2023によると、成人ITP症例の約2/3が慢性ITPに移行するが、小児ITP症例の20～25%が慢性ITPに移行します。免疫性血小板減少症（ITP）の年間発症率は、小児10万人あたり5例、成人10万人あたり2点と推定されています。ステロイド薬には副作用があるため、一般的には血小板刺激薬が処方されます。

市場力学：市場促進要因と市場抑制要因

臨床試験の増加

免疫性血小板減少症は、免疫グロブリン、ステロイド薬、刺激薬で治療され、血液凝固に必要な血小板の体内放出を助ける。成人および小児の原発性免疫性血小板減少症の治療薬として、いくつかの薬剤が臨床試験中です。すべての薬剤は第4相臨床試験段階にあり、間もなく市場に投入される見込みです。

例えば、Octapharmaは、慢性免疫性血小板減少症の小児患者を対象に、PANZYGAの有効性と安全性を評価する第4相臨床試験を実施しています。開始日は2020年1月21日。終了予定日は2024年4月。

さらに、Sobi, Inc.は、成人の慢性（免疫性）血小板減少症ITP患者を対象に、エルトロンボパグまたはロミプロスチムからアバトロンボパグに切り替えた後の安全性および治療満足度を検討する第4相臨床試験を実施しています。試験開始日は2021年3月15日です。終了予定日は2024年2月9日です。

Qidong Gaitianli Medicines Co.Ltd.は、慢性原発性免疫性血小板減少症の小児を対象とした淮希黄顆粒の臨床的有効性と安全性を評価する第4相臨床試験を実施中。試験開始日は2017年11月16日。終了予定日は2024年3月8日です。さらに、創薬の進歩やパイプライン医薬品の増加は、今後の市場を牽引する数少ない要因です。

ステロイド薬の副作用

血小板減少症の治療におけるステロイド薬の副作用には、重篤な出血が含まれます。副腎皮質ステロイド薬の副作用は、治療が長期化するにつれて重篤度が増すため、その管理は困難です。白内障、不眠症、高血圧、糖尿病代謝の変化などの可能性のある副作用は、免疫性血小板減少症の治療のためにステロイド薬を摂取している人にも見られます。

このレポートの詳細について-サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 臨床試験の増加
      • YY
    • 抑制要因
      • ステロイド薬の副作用
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 疾病統計
  • 地域分析
  • 規制分析
  • DMI見解

第6章 COVID-19分析

第7章 薬剤クラス別

  • 免疫グロブリン
  • 副腎皮質ステロイド
    • プレドニン
    • デキサメタゾン
    • その他
  • トロンボポエチン受容体作動薬
    • ロミプロスチム
    • アバトロンボパグ
    • その他
  • 血小板刺激薬
    • エフガルチギモド
    • その他
  • その他

第8章 投与経路別

  • 経口剤
  • 注射剤
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • AbbVie Inc
  • Amgen Inc.
  • Pfizer, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Novartis International AG
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Bristol Myers Squibb Inc
  • F. Hoffmann-La Roche Ltd

第13章 付録

目次
Product Code: PH1914

Overview

Chronic Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder that occurs due to decreased platelet secretion, preventing blood clotting. An average platelet count ranges from approximately 150,000 to 400,000 per blood microliter (µL). If the count is lower than 100,000/µL of blood, the person might suffer from immune thrombocytopenia.

According to the Journal of Yeungnam Medical Science, 2023, approximately 2/3 of adult ITP cases lead to chronic ITP, but 20% to 25% of pediatric ITP cases persist to chronic ITP. The annual incidence of immune thrombocytopenia (ITP) is estimated to be five cases per 100,000 children and two points per 100,000 adults. Platelet-stimulating agents are generally prescribed to the patients as steroidal drugs show side effects.

Market Dynamics: Drivers & Restraints

Increasing clinical trials

Immune thrombocytopenia is treated with immunoglobulins, steroidal drugs, and stimulating medicines, which help the body release enough platelets for blood clotting. Several drugs are under clinical trials for the treatment of primary immune thrombocytopenia in adults as well as in children. All the drugs are in phase 4 clinical trials, which are expected to be released soon in the market.

For instance, Octapharma is conducting phase 4 clinical trials to evaluate the efficacy and safety of PANZYGA in pediatric patients with chronic immune thrombocytopenia. The start date is January 21, 2020. The estimated completion date is April 2024.

Furthermore, Sobi, Inc. is conducting phase 4 clinical trials to determine the safety and treatment satisfaction in adults With chronic (immune thrombocytopenia)ITP After switching to avatrombopag from eltrombopag or romiplostim. The study start date is March 15, 2021. The estimated completion date is February 9, 2024.

Qidong Gaitianli Medicines Co., Ltd is conducting phase 4 clinical trials to evaluate the clinical efficacy and safety of Huaiqihuang granule for the treatment of children with chronic primary immune thrombocytopenia. The study start date is November 16, 2017. The estimated completion date is March 8, 2024. Furthermore, increasing advancements in drug discoveries, and increasing pipeline drugs are few factors that drive the market in the forthcoming period.

Side effects of steroidal drugs

Side effects of steroidal drugs in treating thrombocytopenia include severe bleeding. The side effects from corticosteroids are challenging to manage because they grow in severity as the treatment extends for a long time. The possible side effects, such as cataracts, insomnia, hypertension, changes in diabetic metabolism, etc, are also seen in people who consume steroidal drugs to treat immune thrombocytopenia.

For more details on this report - Request for Sample

Segment Analysis

The global chronic immune thrombocytopenia are segmented based on drug class, route of administration, distribution channel, and region.

The Platelet stimulating agents segment accounted for approximately 42.7% of the market share

Platelet-stimulating agents are expected to hold the largest market share due to their efficacy in treating thrombocytopenia. Unlike corticosteroids, platelet-stimulating drugs are more efficient with fewer side effects. The launch of medications with more effectiveness and safety helps in the better treatment of thrombocytopenia in adults and children.

In October 2022, Grifols' TAVLESSE (fostamatinib) received NICE (National Institute for Health and Care Excellence) recommendation for treating refractory chronic immune thrombocytopenia.

In April 2023, Kissei Pharmaceutical Co., Ltd. Launched TAVALISSE tab 100mg and 150mg for chronic idiopathic thrombocytopenic purpura.

Geographical Analysis

North America accounted for approximately 39.8% of the market share in 2022

North America is expected to hold the largest region in the market due to the prevalence of thrombocytopenia in the US population. In children, the annual incidence is estimated to be between 1 and 6.4 cases per 100,000 people.

In adults, the annual incidence is estimated to be between 1 and 6 cases per 100,000 people. However, ITP is more of a chronic disease in adults, so the prevalence is approximately 12 per 100,000 cases. The overall incidence in adults occurs in persons over 60 years old.

According to the Journal of Hematology and Oncology, a 2023 study revealed a 1.3-2.2-fold increase in the mortality rate for adult ITP patients compared to the general population due to infection and other cardiovascular events.

COVID-19 Impact Analysis:

COVID-19 impacted the immune thrombocytopenia market due to the disruption in the supply chain. Due to the shift in research and development focus toward developing drugs and vaccines for COVID-19, the study was halted during the pandemic period. The lockdown was implemented worldwide, postponing the diagnosis of thrombocytopenia to the later stages.

Competitive Landscape

The major global players in the chronic immune thrombocytopenia market include: AbbVie Inc, Amgen Inc., Pfizer, Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Novartis International AG, Johnson & Johnson Services, Inc., Merck & Co., Inc., Bristol Myers Squibb Inc, F. Hoffmann-La Roche Ltd among others.

Key Developments

  • In August 2023, InnoCare Pharma released 2023 interim results as of 30 June 2023. The Company has achieved proof of concept (PoC) of orelabrutinib for the treatment of primary immune thrombocytopenia purpura (ITP) and the Phase III registrational trial is ongoing in China.

Why Purchase the Report?

  • To visualize the global chronic immune thrombocytopenia market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chronic immune thrombocytopenia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global chronic immune thrombocytopenia market report would provide approximately 61 tables, 59 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing clinical trials
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of steroidal drugs
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Disease Statistics
  • 5.5. Regional Analysis
  • 5.6. Regulatory Analysis
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Immunoglobulins*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Corticosteroids
    • 7.3.1. Prednisone
    • 7.3.2. Dexamethasone
    • 7.3.3. Others
  • 7.4. Thrombopoietin Receptor Agonists
    • 7.4.1. Romiplostim
    • 7.4.2. Avatrombopag
    • 7.4.3. Others
  • 7.5. Platelet Stimulating Agents
    • 7.5.1. Efgartigimod
    • 7.5.2. Others
  • 7.6. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Injectables
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AbbVie Inc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Amgen Inc.
  • 12.3. Pfizer, Inc.
  • 12.4. Samsung Bioepis Co., Ltd.
  • 12.5. Sanofi S.A.
  • 12.6. Novartis International AG
  • 12.7. Johnson & Johnson Services, Inc.
  • 12.8. Merck & Co., Inc.
  • 12.9. Bristol Myers Squibb Inc
  • 12.10. F. Hoffmann-La Roche Ltd

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us